Stéphane Hua1, Selena Vigano1, Samantha Tse1, Ouyang Zhengyu1, Sean Harrington1, Jordi Negron1, Pilar Garcia-Broncano1,2, Giulia Marchetti3, Miguel Genebat4, Manuel Leal4, Salvador Resino2, Ezequiel Ruiz-Mateos4,5, Mathias Lichterfeld1,6, Xu G Yu1,6. 1. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge. 2. Unit of Viral Infection and Immunity, National Center for Microbiology, Institute of Health Carlos III, Majadahonda, Madrid, Spain. 3. Department of Health Sciences, Clinic of Infectious and Tropical Diseases, San Paolo Hospital, University of Milan, Italy. 4. Laboratory of Immunovirology, University of Seville, Spain. 5. Clinic Unit of Infectious Diseases, Microbiology and Preventive Medicine, Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/Spanish National Research Council (CSIC)/University of Seville, Spain. 6. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
Background: Interferon alpha (IFN-α) can potently reduce human immunodeficiency virus type 1 (HIV-1) replication in tissue culture and animal models, but may also modulate residual viral reservoirs that persist despite suppressive antiretroviral combination therapy. However, mechanisms leading to viral reservoir reduction during IFN-α treatment are unclear. Methods: We analyzed HIV-1 gag DNA levels in CD4 T cells by digital droplet polymerase chain reaction and CD8 T-cell and natural killer (NK) cell phenotypes by flow cytometry in a cohort of antiretroviral therapy-treated HIV-1/hepatitis C virus-coinfected patients (n = 67) undergoing treatment for hepatitis C infection with pegylated IFN-α and ribavirin for an average of 11 months. Results: We observed that IFN-α treatment induced a significant decrease in CD4 T-cell counts (P < .0001), in CD4 T-cell-associated HIV-1 DNA copies (P = .002) and in HIV-1 DNA copies per microliter of blood (P < .0001) in our study patients. Notably, HIV-1 DNA levels were unrelated to HIV-1-specific CD8 T-cell responses. In contrast, proportions of total NK cells, CD56brightCD16- NK cells, and CD56brightCD16+ NK cells were significantly correlated with reduced levels of CD4 T-cell-associated HIV-1 DNA during IFN-α treatment, especially when coexpressing the activation markers NKG2D and NKp30. Conclusions: These data suggest that the reduction of viral reservoir cells during treatment with IFN-α is primarily attributable to antiviral activities of NK cells.
Background: Interferon alpha (IFN-α) can potently reduce human immunodeficiency virus type 1 (HIV-1) replication in tissue culture and animal models, but may also modulate residual viral reservoirs that persist despite suppressive antiretroviral combination therapy. However, mechanisms leading to viral reservoir reduction during IFN-α treatment are unclear. Methods: We analyzed HIV-1 gag DNA levels in CD4 T cells by digital droplet polymerase chain reaction and CD8 T-cell and natural killer (NK) cell phenotypes by flow cytometry in a cohort of antiretroviral therapy-treated HIV-1/hepatitis C virus-coinfectedpatients (n = 67) undergoing treatment for hepatitis C infection with pegylated IFN-α and ribavirin for an average of 11 months. Results: We observed that IFN-α treatment induced a significant decrease in CD4 T-cell counts (P < .0001), in CD4 T-cell-associated HIV-1 DNA copies (P = .002) and in HIV-1 DNA copies per microliter of blood (P < .0001) in our study patients. Notably, HIV-1 DNA levels were unrelated to HIV-1-specific CD8 T-cell responses. In contrast, proportions of total NK cells, CD56brightCD16- NK cells, and CD56brightCD16+ NK cells were significantly correlated with reduced levels of CD4 T-cell-associated HIV-1 DNA during IFN-α treatment, especially when coexpressing the activation markers NKG2D and NKp30. Conclusions: These data suggest that the reduction of viral reservoir cells during treatment with IFN-α is primarily attributable to antiviral activities of NK cells.
Authors: Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard Journal: Proc Natl Acad Sci U S A Date: 2008-10-20 Impact factor: 11.205
Authors: Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks Journal: Clin Infect Dis Date: 2013-12-12 Impact factor: 9.079
Authors: Thomas A Rasmussen; Martin Tolstrup; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Ajantha Solomon; Anni Winckelmann; Sarah Palmer; Charles Dinarello; Maria Buzon; Mathias Lichterfeld; Sharon R Lewin; Lars Østergaard; Ole S Søgaard Journal: Lancet HIV Date: 2014-09-15 Impact factor: 12.767
Authors: Hiroshi Takata; Supranee Buranapraditkun; Cari Kessing; James L K Fletcher; Roshell Muir; Virginie Tardif; Pearline Cartwright; Claire Vandergeeten; Wendy Bakeman; Carmen N Nichols; Suteeraporn Pinyakorn; Pokrath Hansasuta; Eugene Kroon; Thep Chalermchai; Robert O'Connell; Jerome Kim; Nittaya Phanuphak; Merlin L Robb; Nelson L Michael; Nicolas Chomont; Elias K Haddad; Jintanat Ananworanich; Lydie Trautmann Journal: Sci Transl Med Date: 2017-02-15 Impact factor: 17.956
Authors: Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly Journal: Nat Med Date: 2009-06-21 Impact factor: 53.440
Authors: James P Williams; Jacob Hurst; Wolfgang Stöhr; Nicola Robinson; Helen Brown; Martin Fisher; Sabine Kinloch; David Cooper; Mauro Schechter; Giuseppe Tambussi; Sarah Fidler; Mary Carrington; Abdel Babiker; Jonathan Weber; Kersten K Koelsch; Anthony D Kelleher; Rodney E Phillips; John Frater Journal: Elife Date: 2014-09-12 Impact factor: 8.140
Authors: Alison L Hill; Daniel I S Rosenbloom; Edward Goldstein; Emily Hanhauser; Daniel R Kuritzkes; Robert F Siliciano; Timothy J Henrich Journal: PLoS Pathog Date: 2016-04-27 Impact factor: 6.823
Authors: Maja Kiselinova; Ward De Spiegelaere; Maria Jose Buzon; Eva Malatinkova; Mathias Lichterfeld; Linos Vandekerckhove Journal: PLoS Pathog Date: 2016-03-03 Impact factor: 6.823
Authors: Emmanouil Papasavvas; Livio Azzoni; Andrew V Kossenkov; Noor Dawany; Knashawn H Morales; Matthew Fair; Brian N Ross; Kenneth Lynn; Agnieszka Mackiewicz; Karam Mounzer; Pablo Tebas; Jeffrey M Jacobson; Jay R Kostman; Louise Showe; Luis J Montaner Journal: J Immunol Date: 2019-06-28 Impact factor: 5.422
Authors: Emmanouil Papasavvas; Livio Azzoni; Amélie Pagliuzza; Mohamed Abdel-Mohsen; Brian N Ross; Matthew Fair; Bonnie J Howell; Daria J Hazuda; Nicolas Chomont; Qingsheng Li; Karam Mounzer; Jay R Kostman; Pablo Tebas; Luis J Montaner Journal: AIDS Res Hum Retroviruses Date: 2021-01-29 Impact factor: 1.723
Authors: Nicolas Huot; Steven E Bosinger; Mirko Paiardini; R Keith Reeves; Michaela Müller-Trutwin Journal: Front Immunol Date: 2018-04-19 Impact factor: 7.561